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and rituximab have been reported to overcome renal transplant hyperacute rejection. A retro-
spective caseecontrol study was performed to assess the results and complications of renal
transplantation with desensitization therapy for donor-specific antibody (DSA) in a transplant
center in Asia, where donor exchange was usually not allowed.
Methods: Between January 2007 and December 2013, 22 patients with DSA received live-donor
renal transplantation after desensitization (DSA group). During the same period, the DSA group
was compared to the NSA group (152 renal transplants) who had no specific antibody to the
donors (66 from deceased donors and 86 from living relatives). Rejection, renal function, graft
and patient survival rates, infection, and cancer incidence were reviewed and analyzed from
medical records.
Results: The DSA group (46.8%) had significantly higher acute rejection rates than the NSA
group (13.7%) at the 1-year follow-up. The estimated renal function, 5-year graft, and patient
survival rates were comparable between the groups. The DSA group (19.6%) had significantly
higher 5-year de novo cancer incidence than the NSA group (8.5%; p Z 0.028); three patients
of the DSA group developed urothelial carcinoma 17.0  3.0 months after transplantation. By
using stepwise Cox regression analysis, desensitization therapy was identified as the sole inde-
pendent risk factor for post-transplant urothelial carcinoma.nd methods described in our manuscript have not been previously published even in an abstract form,
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Renal transplantation across DSA barrier 427Conclusion: When compared to renal transplantation without DSA, desensitization therapy for
DSA resulted in equivalent renal transplant outcome but potentially increased risk of urothelial
carcinoma after transplantation.
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Donor-specific antibody (DSA) against human leukocyte
antigens (HLA) has been recognized as one of the most
important obstacles to successful renal transplantation.
Renal transplantation with DSA could lead to hyperacute
rejection or early antibody-mediated rejection (AMR) and
result in premature transplant failure.1,2 During the past
10 years, the development of desensitization protocols has
explored the possibility of renal transplantation across DSA
and has demonstrated encouraging short-term outcomes in
highly-sensitized transplant candidates.3
Desensitization regimens including use of intravenous im-
mune globulin and rituximab have been shown to overcome
DSA and AMR. In 2003, Jordan et al4 reported that an intra-
venous immunoglobulin (IVIG) treatment could inhibit cross-
match positivity and allow for successful transplantation. In
addition, Gloor et al5 developed a desensitization regimen,
including pretransplant plasmapheresis, IVIG, rituximab, and
splenectomy to overcome live donor kidney transplantation
with positive crossmatches. However, chronic AMRafter renal
transplantation remains a serious concern, and the risk of
infectious andneoplastic complications after desensitization,
such as polyoma BK virus-associated nephropathy and uro-
thelial carcinoma, need to be properly addressed.6e8
With the success of ABO-incompatible renal trans-
plantation following rituximab use instead of splenectomy,
our transplant center developed a desensitization protocol
for live donor renal transplantation with DSA in 2007 that
includes plasmapheresis, IVIG, and rituximab.9,10 In this
study, we aimed to present information on graft outcomes
and complications after renal transplantation across DSA
from our transplant center in Asia, where paired exchange
was usually not permitted.
Methods
Study design
Between January 2007 and December 2013, a total of 331
renal transplants were performed at our transplant center.
With the exclusion of ABO incompatible, HLA zero-
mismatched, pediatric, or multiorgan transplants, a total
of 174 ABO-compatible but HLA-mismatched adult renal
transplants, including 66 from deceased donors and 108
from live donors, were reviewed for transplant outcomes.
Of the 108 live donor renal transplant recipients, 22 were
positive for DSA and received desensitization therapy prior
to transplantation. Outcomes of the desensitization ther-
apy were compared between those who underwent renal
transplantation with DSA (DSA group, nZ 22) and thosewith nonspecific antibody to the donors (NSA group,
nZ 152). The NSA group included 86 patients receiving
renal transplants from live donors (L-NSA subgroup) and 66
from deceased donors (D-NSA subgroup).
Pretransplant antibody screening
Patients eligible for live donor transplantation or waiting on
the transplant list were checked for HLA antibody regularly
by flow cytometry panel-reactive antibody (PRA) tests, and
conventional complement-dependent cytotoxicity (CDC)
tests were performed in all cases before renal trans-
plantation. For patients with high levels (> 50%) of pre-
formed PRA or positive CDC, One Lambda LabScreen Single
Antigen tests were used to detect possible DSA. DSA posi-
tivity was defined as any HLA antibody [> 1000 mean
fluorescence intensity (MFI)], targeting the unacceptable
donor antigens as assigned by the single antigen assays.
Desensitization and criteria for transplantation
Before live-donor renal transplantation, patients who were
positive for DSA received desensitization therapy, which was
modified from our protocol for ABO-incompatible renal
transplantation.9 In brief, our desensitization therapy for
DSA includes two doses of rituximab, one dose of 200 mg for
approximately 14 days before transplantation, and the other
during the transplant operation, at least four sessions of
double filtration plasmapheresis (DFPP) and IVIG (2 g/kg in
total) were performed. DFPP was accomplished, as
described previously, using a KM-8800 in a Kuraray plasma-
pheresis system incorporating a Plasmacure PS-06 and an
Evaflux 4A as the plasma fractionator (Kuraray Medical,
Tokyo, Japan).11 Renal transplantation would then be per-
formed when the T-cell CDC against the prospect donor
became negative and the desensitization therapy was
completed. Of note, B-cell CDCwas always intensely positive
after rituximab therapy. For patients who were CDC-positive
even after completion of the desensitization therapy, DFPP
and IVIG (0.5 g/kg after every DFPP) sessionswere performed
again every other day until the CDC test became negative for
T cells. Desensitization therapy would be considered as a
failure (2 cases in this study) and the transplantation was
cancelled when the T-cell CDC was still positive after a total
of eight sessions of DFPP and 4 g/kg of IVIG.
Immunosuppressive therapy and infection
prophylaxis
In addition to the desensitization therapy, patients with
DSA (the DSA group) were administered preconditioning
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zation therapy started. The preconditioning therapy was
basically a tacrolimus-based regimen, including tacrolimus
combined with mycophenolate mofetil and intravenous
methylprednisolone. The NSA group did not receive anti-
body induction, but tacrolimus-based immunosuppression
was initiated after transplantation. The initial target trough
levels for tacrolimus were 8e16 ng/mL, and mycophenolate
mofetil was prescribed at an initial dose of 1e2 g/d. White
blood cell counts were maintained between 4.0  109/L
and 6.0  109/L, unless intolerance occurred or the
maximum dose was reached. Corticosteroids, including
intravenous methylprednisolone and oral prednisolone,
were given according to standard practices. The dose of
prednisolone was reduced to 2.5e5 mg/d at 12 months and
could then be discontinued if significant side effects were
reported. To prevent cytomegalovirus (CMV) infection after
transplantation, valganciclovir (450 mg/d) was adminis-
tered to patients with or without anti-CMV-IgG for 3 months
or 12 months, respectively.
Biopsy and acute rejection
Graft renal biopsy was conducted when allograft rejection
or dysfunction, as defined by elevation of serum crea-
tinine> 20%, significant proteinuria (1 g/d), or unsatisfac-
tory graft function (persistent edema or serum creatinine
>2 mg/dL), was suspected. Protocol biopsy was performed
annually unless the patient refused or an event-based bi-
opsy had been executed in the past 6 months. Pathological
diagnosis of rejection was made based on Banff criteria at
the time of biopsy. Acute rejection episodes (either C4dþ or
not) were treated with a 3-day methylprednisolone (10 mg/
kg/d) pulse therapy. Patients with antibody-mediated
rejection received additional desensitization therapy
after transplantation including four sessions of DFPP and
IVIG (0.5 g/kg after every session of DFPP).
Statistical analysis
Continuous variables are presented as mean  standard
deviation. Unpaired two-tailed t tests and Fisher’s exact
tests were used for normally distributed continuous vari-
ables and categorical variables, respectively. Donor and
recipient renal function was estimated by a four-variable
Modification of Diet in Renal Disease (MDRD) equation.12
The estimated glomerular filtration rate (eGFR) after
graft failure was defined as zero, and patients who died
with functional grafts were considered to have graft fail-
ure. Cancer incidence, graft, and patient survival were
estimated using the KaplaneMeier method. Univariate
analysis with the log-rank test was used to examine the
prognostic significance of desensitization therapy, recipient
sex, donor sex, re-transplantation, acute rejection, and
AMR on cancer incidence. The prognostic significance of age
at transplantation, donor age, and HLA mismatch for post-
transplant cancer was determined by Cox regression.
Stepwise multivariate regression analysis was then applied
to factors with statistical significance in the univariate
analysis to identify the independent factors that showed
statistical significance for post-transplant cancer.Results
Patient characteristics
Patient demographics of the DSA and NSA groups, including
L-NSA and D-NSA subgroups, are summarized in Table 1. The
mean age of the DSA group at transplantation
(46.9  9.0 years) was significantly older than that of the
NSA group (41.7  13.0 years, pZ 0.023). When comparing
subgroups, the mean age of the DSA group was comparable
to that of the D-NSA subgroup (46.0  10.1, pZ 0.709) but
was significantly higher than that of the L-NSA subgroup
(38.4  14.0, p Z 0.008), probably because of a signifi-
cantly higher number of second transplants in the DSA
group (8/22, 36.4%) than that in the NSA group (4/152,
2.6%). There were significantly more female patients in the
DSA group (77.3%, 17/22) than in the NSA group (44.1%, 67/
152; p Z 0.005), and the difference remained statistically
significant when comparisons were made between the two
subgroups (pZ 0.003 for the L-NSA subgroup and pZ 0.025
for the D-NSA).
The distribution of sexes of the donors was not signifi-
cantly different between the DSA and NSA groups, although
there seemed to be more male donors in the D-NSA sub-
group than in the L-NSA subgroup. The mean donor age of
the DSA group (50.2  12.3) was significantly higher than
that of NSA group (44.0  11.8; pZ 0.035), mainly because
of the high number of young donors in the D-NSA subgroup
(p Z 0.003). However, the eGFRs of the donors were
comparable between the two groups of patients including
the subgroups. The DSA group had significantly more HLA
mismatches (3.2  1.4) than the NSA group (2.61  1.1),
especially in the D-NSA subgroup (2.5  1.1). In addition,
the DSA group had significantly higher PRA class I
(71.7  31.9 vs. 8.4  19.6) as well as PRA class II
(63.8  38.0 vs. 7.5  19.0) than the NSA group. Actually,
the DSA group (21/22, 95.5%) included a significantly higher
percentage of patients with experience of blood trans-
fusion when compared to the NSA group (92/152, 60.5%).
Donor-specific antibody and acute rejection
After evaluation and desensitization, none of the patients
in either group presented episodes of hyperacute rejection,
although 16 patients in the DSA group were positive for CDC
before desensitization. Of the 22 patients in the DSA group,
19 were positive for HLA class I DSA, but only nine were
positive for class II. The average MFIs of the DSA group were
4111  4766 (range, 1416e21,751) for the highest HLA class
I DSA and 9473  11,418 (range, 1605e41,118) for the
highest class II DSA. Patients with a strong DSA
(MFI > 10,000) had a 100% rejection rate at 1 month, and
the rejection rates of those with intermediate DSA (MFI
5000e10,000) and low DSA (MFI 1000e5000) were 40% and
15.4%, respectively. The DSA levels were statistically sig-
nificant for acute rejection of the DSA group after desen-
sitization (p Z 0.027).
When compared to the NSA group, patients with DSA had
a significantly higher 1-year acute rejection rate even after
desensitization (46.8% vs 13.7%, p < 0.001; Figure1).
Interestingly, the 1-year incidence of AMR was not as high
Table 1 Patient demographics.
Characteristics NSA (n Z 152) DSA (n Z 22) p-value* (vs DSA)
NSA
L-NSA (n Z 86) D-NSA (n Z 66) L-NSA D-NSA
Age at transplantation 41.7  13.0 46.9  9.0 0.023
[years] 38.4  14.0 46.0  10.1 0.008 0.709
Gender [M:F] 85:67 5:17 0.005
51:35 34:32 0.003 0.025
Donor age [years] 44.0  11.8 50.2  12.3 0.035
46.6  10.3 40.7  12.8 0.159 0.003
Donor gender [M:F] 75:77 11:11 1.000
28:58 47:19 0.143 0.117
Donor MDRD GFR [mL/min] 100.9  47.8 92.1  22.7 0.398
93.8  16.4 110.2  69.3 0.696 0.234
HLA mismatches 2.61  1.1 3.2  1.4 0.022
2.7  1.2 2.5  1.1 0.065 0.015
Blood transfusion history, n (%) 92 (60.5%) 21 (95.5%) <0.001
48 (55.8%) 44 (66.7%) <0.001 0.010
Flow PRA I [%] 8.4  19.6 71.7  31.9 <0.001
3.9  10.1 14.6  26.7 <0.001 <0.001
Flow PRA II [%] 7.5  19.0 63.8  38.0 <0.001
4.310.6 11.925.7 <0.001 <0.001
Re-transplantation (%) 4 (2.6%) 8 (36.4%) <0.001
2 (2.3%) 2 (3.0%) <0.001 <0.001
M, male; F, female; MDRD, modification of diet in renal disease (equation); GFR, glomerular filtration rate; HLA, human lymphocyte
antigen; PRA, panel-reactive antibody.
* Two-tailed Fisher’s exact test was used for categorical variables; two-tailed unpaired t test was used for continuous variables.
Renal transplantation across DSA barrier 429as expected in the DSA group (27.3%), but it was still higher
than that of the NSA group (5.3%, pZ 0.003). As for chronic
AMR after more than 6 months, three patients in the DSA
group (3/22, 13.6%), six in the NSA group (6/152, 3.9%), one
in the L-NSA subgroup, and five in the D-NSA subgroup, had
chronic AMR during the follow-ups; the incidence of chronic
AMR between the DSA and NSA groups did not reach sta-
tistical significance. However, when compared to the L-NSA
subgroup, the DSA group had a significantly higher risk of
chronic AMR (p Z 0.026). Moreover, the average eGFRs of0.000
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Figure 1 KaplaneMeier estimates of the rejection-free sur-
vival rates of the donor-specific antibody (DSA) group, the live
donor subgroup (L-NSA), and diseased donor subgroup (D-NSA)
subgroup.the DSA group were not significantly different from those of
the NSA group 4 years after transplantation, although in the
NSA group, the L-NSA subgroup had significantly (p < 0.05)
better eGFRs than the D-NSA subgroup at 12 months,
24 months, 36 months, and 42 months post-transplant
(Figure 2). The DSA group seemed to have comparable
eGFRs to the L-NSA subgroup in the first year, but the eGFR
of the DSA group dropped and fluctuated between the
levels of those in the L-NSA and D-NSA, possibly because of
acute rejection and anti-rejection treatments. The overall
outcomes of the two groups are summarized in Table 2.Infections and complications
The 5-year graft and patient survival rates between the DSA
and NSA groups, as well as the subgroups, were compara-
ble. One patient from the DSA group had Pneumocystis
jiroveci pneumonia and another had bacterial pneumonia.
All patients in the DSA group are currently surviving, but
two grafts failed because of chronic rejection. As for the
NSA group, three patients with polyoma BK virus-associated
nephropathy, two with CMV pneumonitis, one with Pneu-
mocystis jiroveci pneumonia, and another with tuberculosis
were observed. Five patients of the NSA group died with
functional renal allografts because of cardiovascular events
(nZ 2 patients), acute pancreatitis (nZ 1), pneumonia of
unknown pathogen (nZ 1), and advanced urothelial carci-
noma (nZ 1). However, three of the 22 patients in the DSA
group developed malignancies during a mean follow-up of
51.4  24.4 months, compared with six of the 152 patients
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Figure 2 Modification of diet in renal disease estimated
glomerular filtration rates of the donor-specific antibody (DSA)
group, the live donor subgroup (L-NSA), and diseased donor
subgroup (D-NSA) subgroup. The L-NSA subgroup had signifi-
cantly better eGFRs than the D-NSA subgroup at 12 months,
24 months, 36 months, and 42 months post-transplant.
*p < 0.05.
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Figure 3 KaplaneMeier estimates of the cumulative cancer
incidences of the donor-specific antibody (DSA) group and the
live donor subgroup (L-NSA) and diseased donor subgroup (D-
NSA) subgroup.
430 C.-Y. Yang et al.in the NSA group over 55.7  24.3 months. In the DSA group,
the incidence of post-transplant cancer was 19.6% at
5 years, compared with 8.5% in the NSA group (Figure 3).
The difference in post-transplant cancer incidence be-
tween the two groups was statistically significant
(p Z 0.028).
Urothelial carcinoma accounted for 100% (3/3) of the
pathological diagnoses in the DSA and 50.0% (3/6) of the
NSA groups. However, the three patients in the DSA group
were found to have urothelial carcinoma in the bladder for
two and left kidney for one at 17.0  3.0 months afterTable 2 Outcomes of renal transplantation with or without DSA
Outcomes NSA (n Z 152)
L-NSA (n Z 86) D-NSA
1-yr acute rejection 13.7%
9.5% 19.5%
1-yr antibody-mediated rejection 5.3%
2.3% 9.1%
Chronic AMR after 6 months, n (%) 6 (3.9%)
1 (1.2%) 5 (7.5
1-yr MDRD GFR [mL/min] 58.0  22.7
61.5  21.6 53.5
5-yr graft survival 87.0%
94.4% 78.2%
5-yr patient survival 96.3%
97.6% 94.4%
5-yr cancer incidence 8.5%
9.4% 8.1%
Follow-up [months] 55.7  24.3
54.5  23.1 57.2
AMR, antibody-mediated rejection; MDRD, modification of diet in ren
* Log-rank test was used for survival analysis; two-tailed unpaired ttransplantation as well as three patients in the NSA group (2
in the bladder only and 1 in bilateral kidneys, ureters, and
bladder) at 47.3  13.6 months. The remaining three pa-
tients of the NSA group developed cancer of the endome-
trium, colon, or thyroid at 58 months, 33 months, and
26 months, respectively. Interestingly, eight of the nine
patients with post-transplant cancer in this study were fe-
male. Neither skin cancer nor post-transplant lymphopro-
liferative disease was detected in any of the patients. As
urothelial carcinoma was the major concern of post-
transplant malignancies in the DSA group, we performed
univariate and stepwise regression analyses to identify the
independent risk factors for post-transplant urothelial
carcinoma. We found that age at transplantation, donor
sex, donor age, acute rejection, AMR, HLA mismatch, and
retransplantation were not significantly associated with the.
DSA (n Z 22) p-value* (vs DSA) NDSA
(n Z 66) L-NSA D-NSA
46.8% <0.001
<0.001 0.013
27.3% 0.003
<0.001 0.031
3 (13.6%) 0.089
%) 0.026 0.388
61.2  13.4 0.543
 23.3 0.970 0.171
92.3% 0.975
0.268 0.429
100.0% 0.416
0.511 0.325
19.6% 0.028
0.047 0.078
51.4  24.4 0.444
 25.9 0.571 0.357
al disease (equation); GFR, glomerular filtration rate.
test was used for continuous variables.
Table 3 Univariate analyses of risk factors for urothelial
carcinoma.
Log-rank test Category No. of
patients
5-y incidence
of urothelial
carcinoma (%)
p
Desensitization Yes 22 19.6 0.002
No 152 4.6
Sex Female 85 12.7 0.012
Male 89 0
Renal transplantation across DSA barrier 431development of urothelial carcinomas. Univariate analyses
showed that desensitization therapy (p Z 0.002) and fe-
male sex (p Z 0.012) were significant risk factors for uro-
thelial carcinoma after transplantation (Table 3).
Furthermore, stepwise Cox regression identified desensiti-
zation as the sole independent risk factor for urothelial
carcinoma after transplantation at a risk ratio of 7.81
(p Z 0.010; Table 4).
Discussion
With desensitization protocols including the use of ritux-
imab and IVIG, outcomes of DSA-positive renal trans-
plantation have been encouraging, although the incidences
of AMR remain around 30%.1,8,13 Rituximab, which depletes
CD-20 expressing B cells, has been shown to reduce the
magnitude of HLA antibody rebound after desensitization,
while DSA levels, as Chung et al14 reported, were signifi-
cantly associated with the incidence of acute rejection.15
In addition, with the introduction of IVIG, chronic AMR in
our DSA group was controlled at a lower incidence (13.6%)
than that reported in the study by Yamanaga et al16 (36%),
who did not include IVIG in their desensitization regimen.
The 5-year graft survival rate of renal transplantation with
DSA, in our experience, seemed acceptable (> 90%) and
similar to those without DSA, even though the 1-year acute
rejection rate of the DSA group was still relatively high
(46.8%).17 While bortezomib, a proteasome inhibitor that
depletes plasma cells, has been demonstrated to reduce
HLA antibody levels in highly sensitized transplant candi-
dates, side effects and potential complications of desensi-
tization remain a serious concern.18
The incidence of opportunistic and systemic infections
seemed similar between the desensitized and non-
desensitized groups when strong immunosuppressive agents
sustained the renal allografts in DSA and rejection and favor
long-term graft survival.19 However, pretransplant desen-
sitization therapy was reported to increase the risk of
polyoma BK viremia and associated nephropathy.7,20
Fortunately, we did not encounter any case of BKTable 4 The final model of stepwise Cox regression analysis
analyses.
Cox regression Regression coefficient Standard error
Desensitization 2.11 0.82
CI Z confidence interval.nephropathy in the DSA group, and all of the allografts
survived DSA with the exception of two with chronic AMR.
Nevertheless, the increased acute rejection rate and
comparable graft survival rates of our DSA group suggested
that the potent and sustained immunosuppressive therapy
given controlled the rejection responses. Our DSA group
had a significantly higher incidence of post-transplant
urothelial carcinoma during the follow-up periods,
although cancer risk of the ABO-incompatible renal trans-
plantation did not increase.21,22 Three female patients
from the DSA group had urothelial carcinoma at
17.0  3.0 months post-transplantation. De novo malig-
nancy, especially urothelial carcinoma, after desensitiza-
tion could be a grave threat to highly sensitized renal
transplant patients in Asia, although many factors other
than desensitization have been reported to increase the
risk of urothelial carcinoma.23
While nonmelanoma skin cancer and lymphoproliferative
disorders are prevalent in Western countries, urothelial
carcinoma is very common among Asian renal transplant
patients. Chinese herbal medications containing aristolo-
chic acid could contribute to the higher incidence of uro-
thelial carcinoma in Asian patients.23 Herbal medications
containing aristolochic acid have been demonstrated to be
carcinogenic.24 However, female sex, as demonstrated
statistically, was an independent risk factor for the devel-
opment of urothelial carcinoma after renal trans-
plantation.25 Additionally, a higher risk of post-transplant
malignancy was found in older patients at trans-
plantation.26 Patients with high PRA, which could be caused
by pregnancy and previous transplantation, are unfortu-
nately related to being female and to older age. With fe-
male predominance, older age (more re-transplantation),
and strong immunosuppression, renal transplantation with
DSA could be expected to have an increased risk of post-
transplant urothelial carcinoma.
Immunosuppressive therapy has played an important
role in the occurrence of post-transplant cancers in renal
transplant patients. The incidence of malignancies, as
Berardinelli et al27 showed, was higher in patients treated
with a calcineurin inhibitor (CNI). Furthermore, induction
therapy with a T-cell-depletive biological agent has also
been reported to be associated with post-transplant can-
cer, mostly skin cancer and urothelial cancer.28 Receiving
an even stronger immunosuppressive therapydincluding
rituximab, preconditioning immunosuppression, and more
antirejection therapydthan just induction and a CNI-based
regimen, patients with DSA would require careful surveil-
lance for detection of malignancies after desensitization
and transplantation. Actions should be taken to prevent
post-transplant cancer especially in highly sensitized pa-
tients who undergo desensitization therapy. Previously,
macrocyclic lactone inhibitors of the mammalian target ofof the factors with statistical significance in the univariate
Risk ratio Lower 95% CI Upper 95% CI p
7.81 0.51 3.72 0.010
432 C.-Y. Yang et al.rapamycin signaling pathway, such as sirolimus or ever-
olimus, were shown to exert both anticancer and immu-
nosuppressive effects.29 We recently reported that de novo
therapy with low-dose sirolimus combined with a CNI could
possibly reduce the risk of post-transplant cancer in renal
transplant recipients.30 The higher risk of post-transplant
cancers warrants long-term studies on the effects of
mammalian target of rapamycin inhibitors in the prevention
of cancers after desensitization for DSA.
In conclusion, to overcome complications due to DSA,
desensitization therapy using rituximab and IVIG resulted in
equivalent renal transplant survival rates and function, but
risk of urothelial carcinoma could be higher after renal
transplantation, when compared with those without DSA
and the desensitization therapy.
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